Abstract: A method of producing a protein of interest (POI) by culturing a recombinant eukaryotic cell line comprising an expression construct comprising a regulatable promoter and a nucleic acid molecule encoding a POI under the transcriptional control of said promoter, comprising the steps a) cultivating the cell line with a basal carbon source repressing the promoter, b) cultivating the cell line with a limited amount of a supplemental carbon source de-repressing the promoter to induce production of the POI at a transcription rate of at least 15% as compared to the native pGAP promoter, and c) producing and recovering the POI; and further an isolated regulatable promoter and a respective expression system.

Abstract: At least one embodiment of the present invention relates to new cycloundecadepsipeptide compounds and to the use of said compounds as a medicament, in particular as antiviral agents, more particularly for preventing or treating Hepatitis C infections or HCV induced disorders.

Abstract: The present invention relates to a shuttering element for limiting a section of a trench wall. The shuttering element is characterized by a plurality of shuttering parts which have a plate-shaped base body, consisting of concrete in particular, and are connected to one another at their adjoining horizontal front faces. Furthermore, the invention relates to a shuttering part as well as a method for producing a trench wall in the ground.

Abstract: At least one embodiment of the present invention relates to new cycloundecadepsipeptide compounds and to the use of said compounds as a medicament, in particular as antiviral agents, more particularly for preventing or treating Hepatitis C infections or HCV induced disorders.

Abstract: The present invention relates to a shuttering element for limiting a section of a trench wall. The shuttering element is characterized by a plurality of shuttering parts which have a plate-shaped base body, consisting of concrete in particular, and are connected to one another at their adjoining horizontal front faces. Furthermore, the invention relates to a shuttering part as well as a method for producing a trench wall in the ground.

Abstract: A pro-drug comprising a cyclic undecapeptide wherein the peptide chain thereof comprises at least one amino acid residue, useful as a medicinal product, including use for treatment of pathological conditions of the eye.

Abstract: The invention relates to cyclosporin derivatives, whereby the peptide chain thereof comprises at least one pseudo-proline type non-natural amino acid radical. The invention also relates to a method for the production of said derivatives.

Abstract: The invention relates to a pro-drug comprising a cyclic undecapeptide wherein the peptide chain thereof comprises at least one amino acid residue of general formula (1) wherein the carbon atom Ca is one of the links in said undecapeptide cycle; —substituents Y individually represent a hydrogen atom or form a bond together; —substitutents R1 and R3 independently represent a hydrogen atom, an aralkyl group, an alkaryl group, a heteroalkyl group, a heterocyclic group, a heterocyclic alkyl group, an alkyl heterocyclic group or an alkyl group having 1-6 carbon atoms which is linear or branched, and which is optionally substituted by at least one of the groups chosen from among —COOH, —CONHR8, —NHCO═NH(NH2), —NHC═NR8(NH2), —NH2, —NHR8, —NR82, —N+R83, —OH, —OPO(OR8)2, —OPO(OH)(OR8), —OPO(OH)2, —OSO(OR8)2, —OSO(OH)(OR8), —OSO(OH)2, and the different salts produced therefrom, each of the substituents R8

Abstract: Use of a compound of formula I 1

Abstract: Use of a compound of formula I wherein R1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R2, R3, R4 and R5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.

Abstract: Use of a compound of formula I 1

Abstract: Use of a compound of formula (I) wherein R1 is an optionally substituted straight- or branched carbon chain having 12 to 22 carbon atoms which may be optionally interrupted by an optionally substituted phenylene, and each of R2, R3, R4 and R5, independently, is H or lower alkyl, in free form or in pharmaceutically acceptable salt form, in the prevention or treatment of chronic rejection in a recipient of organ or tissue allo- or xenotransplant, or of acute rejection in a xenograft transplant recipient.

Abstract: It has been found that nonimmunosuppressive, cyclophilin-binding cyclosporins are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such cyclosporins include novel Ciclosporin derivatives modified at the 4- and/or 5-positions.

Abstract: A new method of measuring blood levels of immunophilin-binding pharmaceuticals, e.g., cyclosporins, rapamycins, and FK506 compounds is provided, comprising the novel step of displacing the pharmaceutical from its immunophilin by using a binding competitor, thereby eliminating the need for an extraction step and enhancing the simplicity and accuracy of the assay. Assay kits comprising a binding competitor and a receptor, e.g., a monoclonal antibody, which binds to the pharmaceutical but not significantly to the binding competitor are also provided, as are new uses of immunophilin-binding compounds as binding competitors in such assays.

Abstract: It has been found that nonimmunosuppressive, cyclophilin-binding cyclosporins are useful in the treatment and prevention of AIDS and AIDS-related disorders. Such cyclosporins include novel Ciclosporin derivatives modified at the 4- and/or 5-positions.

Abstract: Nonimmunosuppressant cyclosporin derivatives having cyclophilin-binding activity, for example, the compound, ?MeIle!.sup.4 -ciclosporin, are useful in inhibiting HIV-1 replication in treating AIDS and AIDS related disorders.

Abstract: Novel monoclonal antibodies capable of distinguishing between cyclosporins, e.g. Cyclosporine, and metabolites, e.g. Cyclosporins 17 and 18, are produced, e.g. starting from novel cyclosporins having an activated coupling group, e.g. activated carboxy group, e.g. (i) [(O-succinimidooxysuccinyl)-Thr].sup.2 -Cyclosporine and (ii) [(N-.epsilon.-succinimidooxysuccinyl)-(D)Lys].sup.8 -Cyclosporine. Cyclosporin starting materials required for the production of cyclosporins of type (ii), e.g. [(D)Lys].sup.8 -Cyclosporine are also new and additionally have utility in the preparation of novel labelled cyclosporin derivatives, as well as antibodies and antisera generally. Also claimed are novel antigenic conjugates and hybridoma cell lines used in the production of antibodies and antisera as aforesaid as well as assay kits comprising novel antisera, antibodies and/or labelled cyclosporins as aforesaid.

Abstract: Cyclosporins wherein the amino acid residue at the 8-position is a (D)-acyloxy-.alpha.-amino acid residue, typically of formula ##STR1## wherein X=--MeBmt-- or --dihydro--MeBmt--, Y=--.alpha.Abu--, --Ala--, --Thr--, --Val-- or --Nva--, Z=--Val-- or --Nva-- and Q=R.sub.1 --CO--O--CH(R.sub.2)--CH(CO--)--NH-- wherein R.sub.1 =H, C.sub.1-4 alkyl or phenyl and R.sub.2 =H or CH.sub.3, possess immunosuppressive, anti-inflammatory and anti-parasitic activity.

Abstract: Cyclosporins wherein the amino acid residue at the 8-position is a (D)-acyloxy-.alpha.-amino acid residue, typically of formula ##STR1## wherein X=-MeBmt- or -dihydro-MeBmt-, Y=-.alpha.Abu-, -Ala-, -Thr-, -Val- or -Nva-, Z=-Val- or -Nva- and Q=R.sub.1 --CO--O--CH(R.sub.2)--CH(CO--)--NH--wherein R.sub.1 =H, C.sub.1-4 alkyl or phenyl and R.sub.2 =H or CH.sub.3, possess immunosuppressive, anti-inflammatory and anti-parasitic activity.

Abstract: A method for the total synthesis of cyclosporins, in particular Cyclosporin A, cyclosporins produced in accordance with the method of the invention and novel intermediates, in particular novel [1S, 2R, 3R]- and [1R, 2S, 3S]-1-nitrilo-1-carbonyl-3-methyl-2-oxy-heptanes and -hept-5-enes, employed in the method of the invention.